Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 1 , Pages 78-86 , May 2010

Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial

  • Ali Darabi

      Affiliations

    • WPAHS, Core Lab., Pittsburgh, PA 15212, USA
    • ,
  • Didier Hocquet

      Affiliations

    • University Hospital, 25030 Besançon, France
    • Corresponding Author InformationCorresponding author. Laboratoire de Bactériologie, Hôpital Jean Minjoz, University of Franche-Comté, 25030 Besançon Cedex, France. Tel.: +33-3-81668286; fax: +33-3-81668914.
    • ,
  • Michael J. Dowzicky

      Affiliations

    • Pfizer Inc., Collegeville, PA 19424, USA

Received 16 June 2009 ,Accepted 6 December 2009.

References 

  1. Adam D. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 2002;50:1–5
  2. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 2009;63:52–61
  3. Biedenbach DJ, Jones RN. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 2003;46:55–61
  4. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 2005;55:944–949
  5. Casellas JM, Bantar C, Duret F Argentinean Collaborative Test Group. Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicentre study. J. Chemother. 2007;19:482–487
  6. Cerquetti M, Giufrè M, Cardines R, Mastrantonio P. First characterisation of heterogeneous resistance to imipenem in invasive nontypeable Haemophilus influenzae isolates. Antimicrob. Agents Chemother. 2007;51:3155–3161
  7. Chiu CH, Su LH, Huang YC, Lai JC, Chen HL, Wu TL, et al. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae in Taiwan. Antimicrob. Agents Chemother. 2007;51:3404–3406
  8. Clinical and Laboratory Standards Institute (CLSI) . Performance standard for antimicrobial susceptibility testing, document M100-S16. Wayne, PA: CLSI; 2006;
  9. Clinical and Laboratory Standards Institute (CLSI) . Performance standard for antimicrobial susceptibility testing, document M100-S18. Wayne, PA: CLSI; 2008;
  10. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int. J. Antimicrob. Agents. 2005;25:523–529
  11. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA. Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 2003;47:972–978
  12. Doern GV, Richter SS, Miller A, Miller N, Rice C, Heilmann K, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin. Infect. Dis. 2005;41:139–148
  13. Draghi DC, Tench S, Dowzicky MJ, Sahm DF. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy. 2008;54:91–100
  14. Felmingham D, Canton R, Jenkins SG. Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. J. Infect. 2007;55:111–118
  15. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 2005;52:187–193
  16. Gonullu N, Catal F, Kucukbasmaci O, Ozdemir S, Torun MM, Berkiten R. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey. Chemotheraphy. 2009;55:161–167
  17. Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, et al. Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study. Mikrobiyol. Bul. 2008;42:537–544
  18. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis. 2001;32:S81–S93
  19. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J. Antimicrob. Chemother. 2002;50(Suppl S1):49–59
  20. Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 2003;47:373–376
  21. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolates in Korea. Antimicrob. Agents Chemother. 2007;51:453–460
  22. Ko KS, Song JH, Lee MY, Park S, Kwon KT, Heo ST, et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn. Microbiol. Infect. Dis. 2006;55:337–341
  23. Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, et al. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb. Drug Resist. 2006;12:130–135
  24. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007;44(Suppl 2):S27–S72
  25. Marchese A, Schito GC. Recent findings from multinational resistance surveys: are we ‘PROTEKTed’ from resistance?. Int. J. Antimicrob. Agents. 2007;29(Suppl 1):S2–S5
  26. McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs. 2008;68:2633–2644
  27. Miyazaki S, Fujikawa T, Kanazawa K, Yamaguchi K. In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including β-lactamase–negative ampicillin-resistant strains. J. Antimicrob. Chemother. 2001;48:723–726
  28. Morrissey I, Maher K, Williams L, Shackcloth J, Felmingham D, Reynolds R on behalf of the BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999–2007. J. Antimicrob. Chemother. 2008;62(Suppl 2):ii97–ii103
  29. Paul M, Weinberger M, Siegman-Igra Y, Lazarovitch T, Ostfeld I, Boldur I, et al. Acinetobacter baumannii: emergence and spread in Israeli hospitals 1997–2002. J. Hosp. Infect. 2005;60:256–260
  30. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for nonsusceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2007;51:2065–2069
  31. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 2009;15(Suppl 3):7–11
  32. Rello J. Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Crit. Care. 2008;12(Suppl 6):S2
  33. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin. Infect. Dis. 2009;48:e23–e33
  34. Sahm DF, Brown NP, Draghi DC, Evangelista AT, Cheung Yee Y, Thornsberry C. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST surveillance initiative, 2001–2005. Postgrad. Med. 2008;120(Suppl 3):8–15
  35. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad. Med. 2008;120(Suppl 3):16–24
  36. Sanbongi Y, Suzuki T, Osaki Y, Senju N, Ida T, Ubukata K. Molecular evolution of β-lactam resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan. Antimicrob. Agents Chemother. 2006;50:2487–2492
  37. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2008;61:329–338
  38. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 2007;20:368–389
  39. Tsao SM, Lin HC, Lee CM, Hsu GJ, Chen CM, Sun W, et al. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci. Int. J. Antimicrob. Agents. 2008;32(Suppl 3):S184–S187
  40. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 2003;47:665–669
  41. Wimmerstedt A, Kahlmeter G. Associated antimicrobial resistance in Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae and Streptococcus pyogenes. Clin. Microbiol. Infect. 2008;14:315–321
  42. Wyeth Pharmaceuticals Inc . Tygacil prescribing information. Philadelphia, PA, USA. http://www.tygacil.com2009;(Last accessed 7 May 2009)

☆ TEST is funded by Wyeth Pharmaceuticals. Writing and data management services were also funded by Wyeth Pharmaceuticals.

PII: S0732-8893(09)00486-6

doi: 10.1016/j.diagmicrobio.2009.12.009

Diagnostic Microbiology & Infectious Disease
Volume 67, Issue 1 , Pages 78-86 , May 2010

Article Tools